| Literature DB >> 23405191 |
Cheikh Loucoubar1, Laura Grange, Richard Paul, Augustin Huret, Adama Tall, Olivier Telle, Christian Roussilhon, Joseph Faye, Fatoumata Diene-Sarr, Jean-François Trape, Odile Mercereau-Puijalon, Anavaj Sakuntabhai, Jean-François Bureau.
Abstract
There exists great disparity in the number of clinical P. falciparum episodes among children of the same age and living in similar conditions. The epidemiological determinants of such disparity are unclear. We used a data-mining approach to explore a nineteen-year longitudinal malaria cohort study dataset from Senegal and identify variables associated with increased risk of malaria episodes. These were then verified using classical statistics and replicated in a second cohort. In addition to age, we identified a novel high-risk group of children in whom the history of P. falciparum clinical episodes greatly increased risk of further episodes. Age and a high number of previous falciparum clinical episodes not only play major roles in explaining the risk of P. falciparum episodes but also are risk factors for different groups of people. Combined, they explain the majority of falciparum clinical attacks. Contrary to what is widely believed, clinical immunity to P. falciparum does not de facto occur following many P. falciparum clinical episodes. There exist a sub-group of children who suffer repeated clinical episodes. In addition to posing an important challenge for population stratification during clinical trials, this sub-group disproportionally contributes to the disease burden and may necessitate specific prevention and control measures.Entities:
Mesh:
Year: 2013 PMID: 23405191 PMCID: PMC3566008 DOI: 10.1371/journal.pone.0055666
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
List of explanatory categorical variables.
| Categorical (nominal) Variables | No of levels |
| House | 36 |
| Independent Family | 12 |
| Sex | 2 |
| Haemoglobin Type (AA,AS,SS,AC,SC) | 5 |
| ABO blood group | 4 |
| G6PD Haplotype (on 4 SNPs: G6PD-376 | 11 |
| PMI | 2 |
| POI | 2 |
| Birth during the project | 2 |
|
|
|
| Drug treatment period | 4 |
| Year | 19 |
| Trimester | 4 |
| ABO-261 | 3 |
| ABO-297 | 3 |
| ABO-467 | 3 |
| ABO-526 | 3 |
| ABO-771 | 3 |
| Alpha globin-3.7deletion | 3 |
| G6PD-202 | 3 |
| G6PD-376 | 3 |
| G6PD-542 | 3 |
| G6PD-968 | 3 |
Note.-G6PD = Glucose-6-phosphate dehydrogenase, PMI = P. malariae infection, POI = P. ovale infection.
Position on the amino-acid sequence.
List of explanatory continuous variables.
| Continuous Variables | Mean | Median | Min | Max |
| Age (year) | 23.14 | 17.06 | 0 | 97.88 |
| Mean genetic relatedness (Pedigree-based) | 0.012 | 0.012 | 0.001 | 0.028 |
| Mean genetic relatedness IBD-based) | 0.008 | 0.008 | 0.002 | 0.025 |
| Nb. of total PMI | 4.1 | 1 | 0 | 44 |
| Time since first PMI (year) | 6.67 | 5.95 | 0 | 18.51 |
| Nb. of total POI | 1.33 | 0 | 0 | 11 |
| Time since first POI (year) | 6.2 | 5.55 | 0 | 18.51 |
| Exposure (number of days present in the village) per trimester | 81.65 | 91 | 1 | 92 |
| Distance to animal enclosure (meters) | 322 | 271 | 1 | 765 |
| Distance to toilets (meters) | 326 | 280 | 1 | 774 |
| Distance to house's tree (meters) | 344 | 311 | 1 | 759 |
| Distance to wells (meters) | 365 | 453 | 17 | 719 |
| Distance to all (animals, toilets, house's tree, wells) together (meters) | 329 | 288 | 1 | 774 |
| Nb. of previous PFA | 9.69 | 2 | 0 | 97 |
Note.Mean, median, minimum and maximum of the data are from the 726 participant individuals- IBD-Identity by Descent; PMI = P. malariae infection; POI = P. ovale infection; PFA = P. falciparum clinical episodes.
Data summary of the three analyses of Dielmo village.
| Name of theanalysis | DielmoAll | DielmoNbprPFA | DielmoAge |
| Excludedvariable | None | NbprPFA | Age |
| Nb of validatedrules | 91 | 79 | 62 |
| Coverage (%) | 3521(80.9) | 3118(71.6) | 2612(59.9) |
| Nb of rules withNbprPFA | 60 | 62 | |
| Nb of rules withAge | 50 | 79 | |
| Nb of rules withYear | 38 | 45 | 44 |
Number of previous P. falciparum episodes.
The coverage is the number (percentage) of positive events explained by the analysis.
Figure 1Histogram of the major variables.
Histogram of age (A) and number of previous P. falciparum episodes (B), in the rules defining high risk of P. falciparum episodes produced by “DielmoAll” analysis (red boxes) and in the entire dataset of Dielmo village (black boxes).
Data summary of the five analyses of Ndiop village.
| Name of the analysis | NdiopAll | NdiopNbprPFA | NdiopAge | NdiopYear | NdiopSemester |
| Excluded variable | None | NbprPFA | Age | Year | Semester |
| Nb of validated rules | 60 | 57 | 50 | 44 | 24 |
| coverage (%) | 3998 (82.4) | 3710 (76.5) | 3245 (67.5) | 3714(76.6) | 2049 (42.2) |
| Nb of rules with NbprPFA | 31 | – | 40 | 18 | 10 |
| Nb of rules with Age | 34 | 47 | – | 28 | 13 |
| Nb of rules with Year | 37 | 35 | 33 | – | 20 |
| Nb of rules with Semester | 53 | 53 | 46 | 43 | – |
| Nb of rules with TimeNdiop/Semester | 12 | 9 | 11 | 17 | 24 |
The number of previous P. falciparum episodes.
The coverage is the number (percentage) of positive events explained by the analysis.
Figure 2Odds ratio of having at least one P. falciparum clinical episode during the trimester.
These odds ratios depend on the number of previous P. falciparum clinical episodes in either Dielmo village (A) or Ndiop village (B). Odds ratios were obtained by taking the exponential of the beta coefficients.
Risk factors affecting clinical P. falciparum episodes in Dielmo village (model residuals shown in Figure S1).
| Fixed effects | Estimate | Standard Error | z value | p-value |
| Intercept | −1.39 | 0.36 | −3.91 | 9.22 10−05 |
| NbprPFA_1–2 | 0.90 | 0.14 | 6.56 | 5.46 10−11 |
| NbprPFA_3–5 | 1.55 | 0.14 | 10.735 | <2.0 10−16 |
| NbprPFA_6–9 | 2.06 | 0.15 | 13.84 | <2.0 10−16 |
| NbprPFA_10–12 | 2.16 | 0.17 | 12.54 | <2.0 10−16 |
| NbprPFA_13–16 | 2.29 | 0.18 | 12.99 | <2.0 10−16 |
| NbprPFA_17–21 | 2.52 | 0.18 | 13.84 | <2.0 10−16 |
| NbprPFA_22–27 | 2.56 | 0.19 | 13.59 | <2.0 10−16 |
| NbprPFA_28–34 | 2.21 | 0.21 | 10.77 | <2.0 10−16 |
| NbprPFA_35–45 | 2.61 | 0.22 | 11.74 | <2.0 10−16 |
| NbprPFA_46–55 | 2.30 | 0.25 | 9.05 | <2.0 10−16 |
| NbprPFA_56–89 | 2.76 | 0.30 | 9.09 | <2.0 10−16 |
| Age | −0.33 | 0.02 | −17.39 | <2.0 10−16 |
| Days of presence | 0.01 | 0.004 | 3.15 | 1.62 10−−03 |
| Drug period 2 | 0.25 | 0.14 | 1.835 | 0.07 |
| Drug period 3 | −0.62 | 0.16 | −3.79 | 1.51 10−04 |
| Drug period 4 | −0.88 | 0.17 | −5.09 | 3.56 10−07 |
Random effects: Std. Dev.individuals = 0.58 (n = 285); Std. Dev.house = 0.00 (n = 32).
The numbers after NbprPFA (Number of previous P. falciparum clinical episodes) give the range of the number of previous P. falciparum clinical episodes.
No significant interaction between Age and Drug period.
Risk factors affecting clinical P. falciparum episodes in Ndiop village (model residuals shown in Figure S2).
| Fixed effects | Estimate | Standard Error | z value | p-value |
| Intercept | −2.77 | 0.28 | −9.70 | <2.0 10−16 |
| NbprPFA_1–2 | 0.85 | 0.15 | 5.79 | 7.04 10−09 |
| NbprPFA_3–5 | 1.36 | 0.15 | 9.01 | <2.0 10−16 |
| NbprPFA_6–9 | 1.73 | 0.17 | 10.34 | <2.0 10−16 |
| NbprPFA_10–12 | 2.32 | 0.20 | 11.39 | <2.0 10−16 |
| NbprPFA_13–16 | 2.24 | 0.21 | 10.56 | <2.0 10−16 |
| NbprPFA_17–21 | 2.10 | 0.23 | 9.31 | <2.0 10−16 |
| NbprPFA_22–27 | 2.36 | 0.26 | 9.17 | <2.0 10−16 |
| NbprPFA_28–59 | 2.53 | 0.29 | 8.84 | <2.0 10−16 |
| Age | −0.11 | 0.02 | −4.55 | 5.30 10−06 |
| Semester 2 | 3.08 | 0.09 | 33.55 | <2.0 10−16 |
| Drug period 2 | −0.27 | 0.27 | −1.00 | 0.32 |
| Drug period 3 | −0.95 | 0.29 | −3.29 | 9.93 10−04 |
| Drug period 4 | −2.37 | 0.30 | −7.92 | 2.34 10−15 |
Random effects: Std.Dev.individuals = 0.13 (n = 259); Std.Dev.house = 0.01 (n = 26).
The numbers after NbprPFA (Number of previous P. falciparum clinical episodes) give the range of the number of previous P. falciparum clinical episodes.
No significant interaction between Age and Drug period.
Figure 3Estimated effects (beta coefficients) of having at least one P. falciparum clinical episode during the trimester in different models.
These estimated effects were calculated in either Dielmo village (A to C) or Ndiop village (D to F) for “Age” alone (A and D), “Number of previous PFA” alone (B and E), and both variables (C and F).
Figure 4Age distribution of events present in rules using either “Age” or “Number of previous PFA”, both or neither in “DielmoAll” analysis.
Events are divided into four groups depending on their presence/absence within the two rules, one using “Age” and the other “Number of previous PFA” variables. After verifying by a one-way ANOVA that the four groups have different mean ages (F (3,23770) = 3350.86; P<0.0001), the Scheffe test shows that each of the four groups has a mean age significantly different from the others (P<0.001).